Moderna Inc
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2024, the following officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) of the Company took the following actions regarding trading arrangements with respect to our securities:
On June 10, 2024, Stephane Bancel, our Chief Executive Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between September 25, 2024 and February 27, 2025, the Bancel 10b5-1 Plan provides for the potential sale of up to 150,000 shares of the Company’s common stock. The Bancel 10b5-1 Plan expires on February 27, 2025, or upon the earlier completion of all authorized transactions under the Bancel 10b5-1 Plan.
On June 10, 2024, Shannon Klinger, our Chief Legal Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Klinger 10b5-1 Plan). Between September 12, 2024 and August 15, 2025, the Klinger 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 73,086 shares of the Company’s common stock. The Klinger 10b5-1 Plan expires on August 15, 2025, or upon the earlier completion of all authorized transactions under the Klinger 10b5-1 Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.